Norma Pence

A Food and Drug Administration (FDA) letter warning a company about its marketing of injectable CBD products has led to a voluntary recall that the federal agency announced on Wednesday. Biota Biosciences received the letter last month, with FDA directing the firm to cease sales of its line of CBD vials, which it markets as a pain reliever that serves as an alternative to opioids and can help with detoxification. The agency said the company was violating federal statutes both by engaging in interstate commerce of an unapproved new drug and failing to properly label the products by neglecting to include directions for use. “Injectable drug products can pose a serious risk of harm to users because they are delivered directly into the bloodstream and bypass many of the body’s natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis,” FDA wrote. Biota Biosciences Issues Voluntary Na...

When the COVID-19 outbreak ravaged the global economy, the cannabis sector was still licking its wounds from 2019’s vaping crisis. Here’s an in-depth look at how marijuana businesses reacted to COVID-19 is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs Original Article Source: https://mjbizdaily.com/how-marijuana-businesses-reacted-to-covid-19-pandemic/

Skip to content Nothing Found for ““ Sorry, but nothing matches your search terms Please try again with some different keywords A community connecting cannabis consumers, patients, retailers, doctors, and brands since 2008. Company Company Discover Discover Business Business Legal Legal Copyright © 2020 Weedmaps. & are registered trademarks of Ghost Management Group, LLC. All Rights Reserved. Original Article Source: https://www.marijuana.com/feed/

A document prepared by the chair of the United Nations Commission on Narcotic Drugs (CND) lays out a course to keep on track for December’s key vote on the World Health Organization’s cannabis scheduling recommendations. MJBizDaily takeaway: This is a welcome development for industry stakeholders worried about a delay arising from the coronavirus crisis. The vote […] Week in Review: UN to vote on WHO cannabis plan, MA adult-use sales resume, California localities welcome marijuana & more is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs Original Article Source: https://mjbizdaily.com/week-in-review-un-to-vote-on-who-cannabis-plan-ma-adult-use-sales-resume-california-localities-welcome-marijuana-more/

While state cannabis markets have unique dynamics, sales generally have been strong during the COVID-19 pandemic, according to Nancy Whiteman, CEO of Boulder, Colorado-based edibles company Wana Brands. During a Marijuana Business Daily webinar, Whiteman shared her company’s insights alongside broader data presented by Liz Connors, director of analytics at Seattle-based Headset. Eli McVey, MJBizDaily’s […] COVID-19 impact on marijuana retail sales varies by state is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs Original Article Source: https://mjbizdaily.com/covid-19-impact-on-marijuana-retail-sales-varies-by-state/

In a split decision, the Arkansas Supreme Court ruled that a would-be medical marijuana cultivator who sued the state over alleged unfair business licensing application treatment can proceed – despite objections from the state’s attorney general. Arkansas Attorney General Leslie Rutledge had tried to get the Carpenter Farms lawsuit dismissed by arguing that the state […] Arkansas high court allows marijuana permit dispute to move forward is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs Original Article Source: https://mjbizdaily.com/arkansas-supreme-court-allows-marijuana-permit-dispute-to-move-forward/

Presumptive Democratic presidential nominee Joe Biden’s new plan for people with disabilities involves promoting research into the therapeutic potential of marijuana. The former vice president, who remains opposed to broader cannabis legalization , said he will “ensure people with disabilities have a voice in their government and are included in policy development and implementation.” That includes cannabis policy. “A Biden Administration will prioritize the research needed to advance science-based federal policies related to the use of marijuana for medical conditions, chronic pain, and disabilities,” the plan, released on Thursday, states . Thirty years ago, I proudly cosponsored the landmark Americans with Disabilities Act. It was an enormous step forward, but there’s more work to do. So today, I’m releasing my plan to achieve full participation and equality for people with disabilities: https://t.co/psuNvKzYej — Joe Biden (@JoeBiden) May 28, 2020 This is another example of B...

The Nevada secretary of state’s office is reviewing allegations made by a former MedMen Enterprises executive that the cannabis company’s co-founders made illegal campaign donations to Democratic Gov. Steve Sioslak. The allegations by former MedMen Chief Financial Officer James Parker were contained in a January 2019 lawsuit filed in California and were made public by […] Nevada reviewing alleged campaign illegalities by marijuana MSO MedMen is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs Original Article Source: https://mjbizdaily.com/nevada-reviewing-alleged-illegal-campaign-contributions-by-marijuana-mso-medmen/

More California towns, counties appear ready to put out welcome mat for marijuana businesses is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs Original Article Source: https://mjbizdaily.com/more-california-towns-counties-appear-ready-to-welcome-marijuana-businesses/

Many people have had to take a urine test for cannabis, perhaps as a job requirement. Using the popular procedure, marijuana metabolites can in some cases be detected for weeks after a person’s last use. But here’s a question few may have thought to ask: Can THC be detected in semen? According to a new study by a team of Harvard Medical School researchers, the answer is yes—at least sometimes. In a study of 12 participants who regularly consumed marijuana by inhalation, the researchers were able to detect delta-9 THC, the main psychoactive ingredient in cannabis, in two subjects’ semen samples. And at least one metabolite of THC—what’s left over after the body processes the compound—could be detected in all samples capable of being analyzed. “Two semen samples,” the report says, “had insufficient volume to be analyzed.” Why the focus on THC in semen? In a word, pregnancy. Men of reproductive age, the study’s authors note, “are the most prevalent consumers of marijuana, with 19.4% of ...

By Dennis Thompson HealthDay Reporter THURSDAY, May 28, 2020 (HealthDay News) — Lots of people are using medical marijuana to treat their arthritis and other muscle aches and pains, often without consulting their doctor, a new study reports. As many as 1 in 5 patients who consult an orthopedic surgeon for chronic musculoskeletal pain are using a cannabis product to treat them, Canadian researchers found. “We found 20% had reported past or current use of cannabis with the specific intention to manage pain,” said study author Dr. Timothy Leroux, an orthopedic surgeon at the University of Toronto. “Not just recreational users, but patients who said, ‘I’m using cannabis because I want to improve pain with this condition.’ “ There’s also a lot of interest in medical marijuana among arthritis sufferers who haven’t yet tried it, Leroux and his team found. Two-thirds of nonusers are interested in trying a cannabis product to treat their muscle and joint pain, the researchers report...

Activists behind a marijuana legalization initiative in Arkansas are seeing glimmers of hope that they will be able to qualify for the November ballot despite serious setbacks caused by the coronavirus pandemic. A federal judge ruled on Monday that the secretary of state must accept signatures that were not collected in-person or notarized, as has been required by existing policy, because of excessive burdens that imposes on campaigns amid the health crisis. Legalization advocates say the temporary injunction, which comes before a final ruling, gives them confidence their measure can qualify ahead of a July 3 deadline to submit signatures. Now people can download, print and mail in signed petitions—significantly bolstering the chances the legal cannabis campaign can make up for the petitioning deficit created by stay-at-home orders and social distancing requirements enacted due to the COVID-19 outbreak. In the April lawsuit that brought about the federal injunction (which was not fi...

By Dennis Thompson HealthDay Reporter THURSDAY, May 28, 2020 (HealthDay News) — Lots of people are using medical marijuana to treat their arthritis and other muscle aches and pains, often without consulting their doctor, a new study reports. As many as 1 in 5 patients who consult an orthopedic surgeon for chronic musculoskeletal pain are using a cannabis product to treat them, Canadian researchers found. “We found 20% had reported past or current use of cannabis with the specific intention to manage pain,” said study author Dr. Timothy Leroux, an orthopedic surgeon at the University of Toronto. “Not just recreational users, but patients who said, ‘I’m using cannabis because I want to improve pain with this condition.’ “ There’s also a lot of interest in medical marijuana among arthritis sufferers who haven’t yet tried it, Leroux and his team found. Two-thirds of nonusers are interested in trying a cannabis product to treat their muscle and joint pain, the researchers reporte...

The Drug Enforcement Administration (DEA) is facing yet another marijuana-related lawsuit—and this time, researchers and veterans are challenging the agency’s denial of prior cannabis rescheduling requests. The Scottsdale Research Institute (SRI) filed suit last week in the U.S. Ninth Circuit Court of Appeals, asking for a review of DEA’s scheduling determinations in 2020, 2016 and 1992. In all cases, the agency denied the petitions, citing statutory obligations to maintain the status of cannabis as a Schedule I drug under the Controlled Substances Act. Petitioners are taking exception to the basis of those denials, raising questions about DEA’s reliance on scheduling standards that they feel are arbitrary and misinterpret federal law. In particular, they are seeking reviews of the agency’s claims that marijuana must be strictly scheduled because, the government has claimed, it has no currently accepted medical value and has not been proven to be safe. They also argue that another ...

A scientist in a case that forced the release of a previously “secret” Justice Department document about federally authorized marijuana research this week is now calling on Congress to urge administrative action to more rapidly expand studies into the therapeutic potential of cannabis. Sue Sisley of the Scottsdale Research Institute (SRI) and attorneys representing her facility say the Department of Justice is empowered to waive certain requirements and allow additional researchers to immediately grow their own cannabis for studies without registration under newly proposed regulations or even to obtain products from state-licensed dispensaries, for example. They want lawmakers’ help pressuring the Trump administration to take advantage of a process they say would not necessarily violate international treaties that federal officials have long cited as a reason they’ve been slow to license new cultivators. On Wednesday, the Justice Department’s Office of Legal Counsel (OLC) disclosed...

The Drug Enforcement Administration (DEA) is facing yet another marijuana-related lawsuit—and this time, researchers and veterans are challenging the agency’s denial of prior cannabis rescheduling requests. The Scottsdale Research Institute (SRI) filed suit last week in the U.S. Ninth Circuit Court of Appeals, asking for a review of DEA’s scheduling determinations in 2020, 2016 and 1992. In all cases, the agency denied the petitions, citing statutory obligations to maintain the status of cannabis as a Schedule I drug under the Controlled Substances Act. Petitioners are taking exception to the basis of those denials, raising questions about DEA’s reliance on scheduling standards that they feel are arbitrary and misinterpret federal law. In particular, they are seeking reviews of the agency’s claims that marijuana must be strictly scheduled because, the government has claimed, it has no currently accepted medical value and has not been proven to be safe. They also argue that another s...

For anyone left questioning whether marijuana reform has become a mainstream issue in American politics, look no further than the race for a key Senate seat in Colorado, where incumbent Sen. Cory Gardner (R-CO) and his main rival former Gov. John Hickenlooper (D) are each competing for the cannabis vote this November. In a phone interview with Marijuana Moment on Friday, Gardner discussed his cannabis reform record, his thoughts on the House’s inclusion of his Secure and Fair Enforcement (SAFE) Banking Act in their latest COVID-19 relief package and more. At a time of heightened partisanship, the senator and Hickenlooper are largely on the same page when it comes to marijuana: They agree it should be legal, taxed and regulated, and that federal prohibition needs to end. But when residents of one of the first states to legalize in 2012 hit the polls this year, many will have to decide which candidate—both of whom opposed Amendment 64 when it was initially proposed—has done more for th...